Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Culture-Negative Infective Endocarditis Presenting as ANCA-Positive Glomerulonephritis.

The American journal of case reports·2026
Same author

Neighborhood Opportunity and Mental Health-Related Hospitalization Rates Among Children and Youths in 12 U.S. States.

Psychiatric services (Washington, D.C.)·2026
Same author

Reply to Dissent: Guidelines for Management of Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Balance Versus Bias: Correcting Misinformation About the 2025 ATS Community-Acquired Pneumonia Guidelines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Incorporating Economic Evidence in Clinical Guidelines.

Annals of internal medicine·2026
Same author

Commensal Bacteria: An Under-recognized Cause of Pneumonia.

The Journal of infectious diseases·2026

Related Experiment Video

Updated: Jun 26, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.

Daniel M Musher1, Nancy Logan, Adam M Bressler

  • 1Infectious Disease Section, The Medical Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas 77030, USA. daniel.musher@med.va.gov

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|January 13, 2009
PubMed
Summary

Nitazoxanide shows comparable effectiveness to vancomycin for treating Clostridium difficile infection (CDI). This randomized controlled trial suggests nitazoxanide may be a viable alternative for CDI treatment.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Related Experiment Videos

Last Updated: Jun 26, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Clostridium difficile infection (CDI) is a significant healthcare-associated infection.
  • Vancomycin is the primary US FDA-approved treatment for CDI.
  • Metronidazole is commonly used but may be less effective for severe cases.

Purpose of the Study:

  • To compare the efficacy of nitazoxanide with vancomycin in treating CDI.
  • To evaluate treatment response rates and symptom resolution times.

Main Methods:

  • A prospective, double-blind, randomized controlled trial was conducted.
  • Fifty patients with CDI were randomized to receive either vancomycin or nitazoxanide for 10 days.
  • Treatment response was assessed by symptom absence and recurrence over 31 days.

Main Results:

  • Initial response rates were similar: 74% for vancomycin and 77% for nitazoxanide.
  • Among those completing therapy, response rates were 87% (vancomycin) and 94% (nitazoxanide).
  • Sustained response rates were 78% (vancomycin) and 89% (nitazoxanide), with similar times to symptom resolution.

Conclusions:

  • The study suggests nitazoxanide may be as effective as vancomycin for CDI treatment.
  • While the small sample size limits definitive conclusions on noninferiority, nitazoxanide presents a potential alternative.
  • This trial is the first recent comparison of an agent other than metronidazole against vancomycin for CDI.